AUA 2017: AUA Guideline 2017: Stress Urinary Incontinence
Boston, MA (UroToday.com) This is the 3rd AUA guideline on stress UI (SUI). AUA felt that continual updates are needed as surgical options are evolving. Dr Kobashi reviewed the methodology.
AUA 2017: Long-term combination treatment with solifenacin and mirabegron is effective and well-tolerated in patients with overactive bladder
Boston, MA (UroToday.com) randomized controlled trial parallel group, active-controlled multicenter study to evaluate the safety of long-term combination treatment of solifenacin 5 mg (Soli) and mirabegron 50 mg (Mira) compared with each monotherapy.
AUA 2017: Specific changes in brain activity in women with overactive bladder after successful sacral neuromodulation with Interstim: An fMRI study.
Boston, MA (UroToday.com) The study aim was to measure changes in brain activity associated with sacral neuromodulation (SNS) treatment of OAB. It was hypothesized that SNS treatment with attenuate pre-existing areas of increased brain activity.
AUA 2017: Association between urinary symptom severity and automated segmentation of white matter plaque in women with multiple sclerosis.
Boston, MA (UroToday.com) Multiple sclerosis (MS) is characterized by demyelinated white matter plaque throughout the central nervous system. Patients with MS frequently experience a range of bothersome urinary symptoms.
AUA 2017: Is a Group Learning Behavioral Modification Program Effective and Safe in Reducing Geriatric Urinary Incontinence? A Multi-Center Randomized Controlled Trial
Boston, MA (UroToday.com) This was a multi-center randomized controlled trial of women > 55 yrs who had stress, urgency or mixed urinary incontinence (UI) for at least 3 months and a reported ICIQ-UI SF score of 3 or more (1 or more score for leakage frequency, 2 or more score for volume loss). Study objective was to establish the effectiveness & safety of a Group-administered Behavioral Treatment (GBT) by comparing it to no treatment.